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sociated skin neoplasms with MCPyV suggests a unique sus-
ceptibility of EV patients to infections with MCPyV. Both 
MCPyV and EV-HPV may act as synergistic oncogenic cofac-
tors in the development of EV-associated skin neoplasms. 
 Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Epidermodysplasia verruciformis Lewandowsky-Lutz 
(EV) is a rare autosomal recessive genodermatosis associ-
ated with diminished cell-mediated immunity and high 
susceptibility to infection with specific human papillo-
mavirus (HPV) genotypes  [1, 2] . These HPV types are 
referred to as EV HPV types (also known as   -papilloma-
viruses)  [3] . The most frequent EV HPV types are HPV 
type 5 and type 8  [4] . Uncontrolled HPV infections in
EV patients result in flat warts and seborrheic-keratosis-
like lesions arising during childhood or early adulthood. 
There is a high risk of developing carcinomas in situ 
(Bowen’s disease) and invasive squamous cell carcinomas 
(SCC) later in life, mainly on sun-exposed skin  [5–7] .
 The involvement of HPV in human skin cancer has 
been demonstrated first in patients suffering from EV  [3, 
8] . Of the various EV HPV types, particularly HPV-5 and 
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 Abstract 
 Background: Epidermodysplasia verruciformis (EV) is a rare 
genodermatosis that is characterized by susceptibility to
infection with specific human papillomavirus (HPV) geno-
types. Among polyomaviruses, the novel Merkel cell poly-
omavirus (MCPyV) has been found in different epithelial skin 
neoplasias.  Objective: To examine whether EV is associated 
with cutaneous MCPyV infection.  Methods: We used MCPyV-
specific PCR to study skin neoplasms of 6 congenital EV pa-
tients and of 1 patient with acquired EV.  Results: In all con-
genital EV patients, MCPyV DNA was found in carcinomas in 
situ, in invasive squamous cell carcinomas and in common 
warts. In 4 of these patients, the MCPyV-positive skin lesions 
were from different anatomic locations. In addition, 1 immu-
nosuppressed patient suffering from acquired EV harbored 
MCPyV DNA in 2 common warts. In contrast, 7 normal skin 
samples tested negative for MCPyV DNA. Only 2 out of 24 
carcinomas in situ (8.3%) and 2 out of 30 common warts 
(6.7%) from immunocompetent individuals were positive for 
MCPyV DNA.  Conclusions: The strong association of EV-as-
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HPV-8 have been implicated in malignant transformation 
of EV lesions  [9, 10] . The pathogenetic steps of EV-related 
carcinogenesis are not well understood  [7] . In 2002, fami-
lies with EV were found to have missense mutations in the 
 EVER1/TMC6 or  EVER2/TMC8 genes on chromosome 
17q25  [2] . These genes encode cytoplasmic proteins that 
colocalize with calnexin, an integral membrane protein in 
the endoplasmic reticulum, and are likely to function as 
modifiers of ion channels and to be involved in signal 
transduction. It was proposed that EVER proteins act as 
restriction factors for EV-specific HPV in keratinocytes, 
and that EV represents a primary deficiency in intrinsic 
immunity against certain papillomaviruses  [11] . Apart 
from classical, congenital EV with mutations in the  EVER 
genes, an acquired form of EV (AEV) has recently been 
described in immunosuppressed patients  [12] . Despite its 
rarity, EV was addressed in depth in the recent literature 
because it represents a model for virally mediated cutane-
ous oncogenesis  [13] . However, a unifying pathogenetic 
theory for EV is still lacking, and other pathogens could 
contribute to cutaneous oncogenesis in EV as well.
 Polyomaviruses are small, nonenveloped, double-
stranded DNA viruses. They often persist as latent in-
fections, but are potentially oncogenic and may produce 
tumors upon reactivation, e.g. in immunocompromised 
hosts. The majority of Merkel cell carcinomas (MCC) were 
found to be infected with a novel human skin tropic poly-
omavirus, aptly named Merkel cell polyomavirus (MCPyV) 
 [14] . In addition, MCPyV DNA was detected in nonmel-
anoma skin cancer (NMSC) lesions of both  immuno-
suppressed and immunocompetent individuals  [15–18] .
 In this study we analyzed if EV could be associated 
with an increased susceptibility not only to EV HPV, but 
also to human polyomaviruses, particularly to the poten-
tially oncogenic MCPyV  [19] . We demonstrate that all 6 
of 6 congenital EV patients harbor MCPyV DNA in their 
skin lesions. Our data lead us to suggest a possible in-
volvement of MCPyV in skin cancer development in EV 
patients and underline the need for investigation of ad-
ditional infectious agents associated with this disease.
 Patients and Methods 
 Patients 
 The patient characteristics are summarized in  table 1 . The di-
agnosis of EV was based on characteristic clinical features, histo-
logical findings and in congenital EV patients by identification of 
mutations in the  EVER genes [Burger et al., in preparation]. Pa-
tients No. 1 and 2 were siblings that have been described before  [6] . 
At the time point of this study, patient No. 1 was alive, and we were 
able to confirm her EV genetically by mutation analysis [Burger et 
al., in preparation]. In her late 30s, she first developed hyper- and 
hypopigmented macules on both legs. Over the years, she devel-
oped numerous NMSC lesions, mainly SCC and basal cell carci-
nomas on sun-exposed skin areas. Her sister, patient No. 2, had 
died approximately 20 years before this study was conducted. Sim-
Table 1. P atient characteristics
ID
No.
Sex Age 
years
Diagnosis Local-
ization
VP1 LT1 LT3 HPV EV
1 F 80 SCC temple + + + 5 +
80 AK eyelid + + + –
81 BD, BCC nose – – – 5
81 BD neck – + + 5
82 BD hand + + + 5
82 BD hand + + + 5
2 F 73 SCC face + + + – +
73 SCC face + + + 5
73 SCC face – – – 5
3 M 50 BD back + + + 5 +
50 BD back + + + 5
50 BD leg + + + 5
50 BD leg + + + 5
50 BD leg – + + 5
4 M 48 BD face + + + 5, 8 +
48 AK arm + + + 5, 8
48 AK arm – – – 5, 8
5 M 25 verruca forehead + + + 5 +
6 M 64 verruca arm – – + n.d.* –
7 M 34 verruca neck + + + 8 AEV
37 verruca arm + + + 8 AEV
T he data are from 6 patients (No. 1–6) suffering from various 
skin neoplasms associated with congenital EV. One additional pa-
tient (No. 7) with flat warts suffered from acquired EV (AEV). The 
age of each patient refers to the age at the time of histological di-
agnosis of any skin lesion. Suitability of DNA for analysis was con-
firmed by β-globin PCR. Amplifiable DNA was recovered in all 
study cases (not shown). To detect MCPyV sequences, PCR with 2 
primer sets in the T antigen locus (LT1, LT3) and 1 in the VP1 gene 
(VP1) and direct sequencing of PCR products was performed. In 
all EV patients, we detected MCPyV sequences in at least 1 skin 
lesion. The results of HPV PCR and the HPV types identified by 
sequencing of the PCR products are indicated (HPV).
EV+ = EV genetically confirmed by mutation analysis of the 
EVER genes; EV– = EV genetically not confirmed by mutation 
analysis of the EVER genes, but clinical picture suggestive of EV; 
M = male; F = female; AK = actinic keratosis; BCC = basal cell 
carcinoma; BD = carcinoma in situ (Bowen’s disease); verruca = 
common wart (verruca vulgaris); n.d. = no data. * Several EV 
HPV sequences were detected, but exact HPV types could not be 
determined by sequence analysis.
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ilar to her sister, patient No. 2 had developed multiple NMSC le-
sions, first SCC on her face, but later also at other anatomic loca-
tions. Three archival invasive SCC from her face were available for 
analysis. Patient No. 3 was a 50-year-old Caucasian male suffering 
from multiple disseminated flat warts since early childhood. Over 
the years, he had developed numerous (more than 20) carcinomas 
in situ (Bowen’s disease). We analyzed 5 of his carcinoma in situ 
lesions from various anatomic locations in this study. Patient No. 
4, a 48-year-old Caucasian male, developed the classical EV symp-
toms with multiple precancerous and cancerous skin lesions dur-
ing early adulthood. From patient No. 4, we could examine 1 car-
cinoma in situ and 2 actinic keratoses for the presence of HPV and 
MCPyV. Patient No. 5 was a 25-year-old male EV patient of Turk-
ish origin who clinically suffered from multiple warts out of which 
we analyzed 1. EV patient No. 6 was a 64-year-old Caucasian male 
with a clinical history highly suggestive of congenital EV, although 
a mutation analysis of the  EVER genes was not performed.
 The medical records for all patients were reviewed and the fol-
lowing relevant information was extracted: date of birth, sex, date 
of EV diagnosis, EV mutation analysis, treatment regimens, date 
of diagnosis of skin lesions, histological diagnoses of skin lesions 
and HPV analysis. All skin biopsies were collected for diagnostic 
purposes. The biopsies were formalin fixed, paraffin embedded 
and processed according to standard procedures. All HE-stained 
histology slides were reviewed independently by a board-certified 
pathologist (M.P.) and a board-certified dermatopathologist 
(W.K.). Control skin biopsies including 7 normal skin samples, 24 
carcinomas in situ and 30 common warts of otherwise healthy, 
immunocompetent patients were randomly selected from our ar-
chive (Kempf and Pfaltz Histological Diagnostics)  [16] . These pa-
tients had never been treated with immunosuppressive drugs, nor 
did they suffer from immunodeficiencies or EV.
 This study was approved by the ethics review board of the 
Canton of Zurich, Switzerland. Written informed consent was ob-
tained from all living patients. The study was conducted with 
strict adherence to the Declaration of Helsinki Principles.
 Detection of Polyomavirus DNA by PCR 
 DNA extraction and purification was performed as described, 
and DNA quality was confirmed by   -globin PCR  [20] . For 
MCPyV detection, we used 2 primer sets targeting the T antigen 
locus (LT1, LT3) and 1 targeting the VP1 gene (VP1) of MCPyV, 
as described  [14, 20] . For detection of BK virus (BKV) and JC virus 
(JCV), a nested PCR with P3-P4 and P1-P2 primers was per-
formed as published  [21] . To simultaneously detect the presence 
of KI polyomavirus (KIPyV) and WU polyomavirus (WUPyV), a 
standard PCR with a single primer pair detecting part of the VP1 
region of both viruses was performed as described  [21] .
 Detection of HPV DNA by PCR 
 For HPV detection, we used 3 different protocols, as described 
elsewhere  [16] . To preferentially detect EV HPV types, we used a 
PCR protocol with the outer primer set CP62-CP69 and the inter-
nal nested primer set CP65-CP68  [22] .
 Sequence Analyses 
 Amplified MCPyV and HPV PCR products were purified pri-
or to sequencing, using the High Pure PCR Product Purification 
Kit (Roche, Basel, Switzerland) according to the manufacturer’s 
protocol. PCR products were submitted for automated sequenc-
ing, using a Roche FLX genome sequencer (Microsynth, Balgach, 
Switzerland). The resulting MCPyV DNA sequences were aligned 
against the following reference sequences of the NCBI (National 
Center for Biotechnology Information) Entrez Nucleotide data-
base, using the NCBI BLAST program gb  EU375803.1 Merkel cell 
polyomavirus isolate MCC350, and gb  EU375804.1 Merkel cell 
polyomavirus isolate MCC339. The nucleotide blast database was 
searched to determine the degree of homology of HPV PCR prod-
ucts to known HPV subtypes.
 Statistical Analysis 
 MCPyV DNA prevalence was compared between EV lesions 
and control groups (carcinomas in situ, common warts) using the 
two-sided Fisher exact test. Statistics employed in this study were 
carried out using GraphPad Prism 5 software. p  ! 0.05 was con-
sidered to be statistically significant.
 Immunohistochemistry 
 A monoclonal antibody (CM2B4) that specifically recognizes 
MCPyV large T protein was used for immunohistochemical de-
tection of MCPyV, as described  [23] .
 Results 
 Detection of MCPyV in EV Patients 
 In this study, we analyzed a total of 6 patients diagnosed 
with classical congenital EV. MCPyV DNA was detected 
in all 6 EV patients, in at least 1 skin lesion per patient ( ta- 
ble 1 ;  fig. 1 ). In patients No. 1–4, MCPyV DNA was detect-
ed in multiple skin lesions at various anatomic locations. 
DNA of the other 4 known human polyomaviruses – BKV, 
JCV, KIPyV and WUPyV – was not detected in any of the 
samples (not shown). In all EV patients, EV HPV types 
were detected, consistent with the diagnosis of EV ( table 1 ).
 In order to verify the specificity of the amplified 
MCPyV PCR products and to detect genomic variants
of MCPyV, all MCPyV PCR products were sequenced. 
The VP1 product differed by up to 3 bp from the pre-
dicted MCPyV amplicon of the MCC350 virus ge-
nome (gb  EU375803.1 Merkel cell polyomavirus isolate 
MCC350) found in MCC. The LT1 and LT3 sequences 
differed by up to 6 bp in all cases.
 All EV skin lesions positive for MCPyV LT1 DNA by 
PCR were also tested for expression of MCPyV large T 
protein by immunohistochemistry. We found 2 of the EV 
lesions containing isolated keratinocytes that showed a 
faint reactivity for MCPyV large T protein (online suppl. 
fig. 1, www.karger.com/doi/10.1159/000321880).
 We conclude that MCPyV DNA is widely present in 
skin lesions of EV patients. We found MCPyV DNA only 
in 2 out of 24 carcinomas in situ (8.3%) and in 2 out of 30 
common warts (6.7%) of healthy, immunocompetent pa-
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tients  [16] . In contrast, out of 19 skin neoplasms from 
congenital EV patients, MCPyV was present in 16 lesions 
(84.2%; p  ! 0.0001, Fisher’s exact test) ( table 1 ).
 In SCC and in actinic keratosis, we never detected 
MCPyV DNA. MCPyV DNA was also not detected in 
normal skin samples from healthy individuals (n = 7), but 
in 1 out of 17 psoriatic skin samples. This single MCPyV-
positive psoriasis patient had also been previously diag-
nosed with MCC  [20] .
 Detection of MCPyV in a Patient with AEV 
 EV-like symptoms have also been observed in the set-
ting of immunosuppression, and this entity was suggest-
ed to be called AEV  [12] . In addition to the congenital EV 
patients analyzed in this study, we identified 1 patient 
(No. 7 in  table 1 ) who had developed EV-like symptoms 
during immunosuppressive treatment with azathioprine 
for Crohn’s disease, consistent with the diagnosis of AEV. 
The histopathological findings for this patient were con-
sistent with flat warts resembling EV ( table 1 ).
 We were able to analyze 2 common warts (verrucae vul-
gares) from patient No. 6. MCPyV DNA was detected in 
both lesions from this AEV patient. The MCPyV sequenc-
es showed 99% homology with the MCC350 virus genome 
(gb  EU375803.1 Merkel cell polyomavirus isolate MCC350) 
which had been identified in MCC. DNA of BKV, JCV, 
KIPyV or WUPyV was not detected in any of the samples 
(not shown). In both common warts, we found HPV-8 
DNA, consistent with EV HPV infection under immuno-
suppression and, thus, with the diagnosis of AEV ( table 1 ).
 Discussion 
 In this study, we found that all congenital EV patients 
were harboring MCPyV DNA in their benign and malig-
nant skin lesions, sometimes at different anatomic loca-
tions within the same individual. MCPyV was also de-
tected in one patient with AEV  [12] . Our findings indi-
cate a general – inherited or acquired – susceptibility of 
EV patients to MCPyV infection. MCPyV was always 
present in conjunction with EV HPV types.
 The high detection rate of MCPyV in benign and ma-
lignant skin lesions of EV patients is remarkable, as op-
posed to the low prevalence of MCPyV in NMSC of im-
munosuppressed and immunocompetent patients not suf-
fering from EV. Despite the high seroprevalence of MCPyV 
in adults  [24, 25] , viral DNA is present only in a subset of 
 Fig. 1. Detection of MCPyV DNA in carci-
noma in situ lesions and common warts of 
2 EV patients (No. 3 and 5 in table 1). Ge-
nomic DNA from archival skin biopsies 
was amplified with primers specific for the 
LT1, LT3 or VP1 genes of MCPyV. DNA 
quality was checked by   -globin PCR to 
determine the presence of PCR-amplifi-
able DNA. The PCR products were sepa-
rated on 1.5% agarose gels. DNA marker: 
low-mass DNA Molecular Weight Marker 
VIII (Roche; fragment lengths in base 
pairs are indicated). Lanes 1–5: 5 Bowen-
type carcinoma in situ lesions of patient 
No. 3. Lanes 6 and 7: 2 Bowen-type carci-
noma in situ lesions of 2 different immu-
nocompetent patients. Lanes 8 and 9: 2 in-
vasive SCC of 2 different immunocompe-
tent patients. Lanes 10 and 11: 2 common 
warts of 2 different immunocompetent pa-
tients. Lane 12: common wart of EV pa-
tient No. 5. N = Negative (H 2 O) control;
+ = MCPyV-positive, sequence-confirmed 
MCC control. 
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epithelial skin neoplasms. We and others found MCPyV 
DNA in up to 10% of carcinomas in situ of immuno-
competent and immunosuppressed patients  [15–18] . In-
triguingly, approximately 27% of the European popula-
tion show a polymorphism in one of the  EVER genes  [26] . 
Impaired  EVER function in carriers of such polymor-
phisms could be an explanation for an increased suscepti-
bility to MCPyV infection in a subset of the population. 
MCPyV DNA was not detected in actinic keratosis, in in-
vasive SCC and in normal skin  [16] . In contrast to MCPyV, 
EV HPV is frequently present in NMSC lesions  [27] .
 In line with our findings, MCPyV DNA has recently 
been detected in one EV patient suffering from MCC  [28] . 
As the risk to develop MCC is increased in immunosup-
pressed patients and EV seems to compromise the defense 
mechanisms against viral infections, EV might facilitate 
the development of MCC. However, it still remains to be 
determined if EV patients are more prone to the develop-
ment of MCC. Alternatively, MCPyV as well as EV HPV 
might persist in a ‘dormant’ state in isolated cells and be-
come reactivated under conditions of immunosuppression, 
as described for other members of the polyomavirus family.
 EV results from a genetically determined defect in cell-
mediated, cutaneous immunity  [9] . Inactivating mutations 
in two adjacent genes on chromosome 17q25,  EVER1 
 (TMC6) or  EVER2  (TMC8), have recently been identified 
in EV patients  [2] . It has been hypothesized that these genes 
play a role in regulating the distribution of zinc in the cell 
nucleus. Zinc has been shown to be a necessary cofactor for 
many viral proteins, and the activity of  EVER1/EVER2 ap-
pears to restrict the access of viral proteins to cellular zinc 
stores, limiting their growth  [29] . Therefore, EV can be 
considered a result of a defect in cutaneous immunity that 
leaves afflicted individuals susceptible to persistent infec-
tion not only with EV HPV  [9] , but also with MCPyV. EV 
may not be the only skin disorder with an increased sus-
ceptibility to EV HPV and MCPyV. Both EV HPV type 5 
and MCPyV have recently been detected in psoriatic skin 
lesions  [20, 30–32] . In contrast to EV, there is only a
weak association of MCPyV with psoriasis. Interestingly, 
the susceptibility locus for psoriasis (PSORS2) has been 
mapped to the short arm of chromosome 17q, which also 
contains the EV1 susceptibility locus  [2, 33] . In a similar 
manner, another potential susceptibility locus for psoriasis 
was found on chromosome 2, near the EV2 susceptibility 
locus  [31, 34] . Whether these genetic loci are also suscepti-
bility loci for MCPyV infection, remains to be studied.
 When we tested the skin biopsies of all EV patients by 
immunohistochemistry, using a monoclonal antibody di-
rected against the large T protein of MCPyV  [23] , we de-
tected a signal in isolated keratinocytes of some patients. 
As suggested before, MCPyV copy numbers are probably 
low in these skin lesions, hampering immunohistochem-
ical detection of the virus  [16, 23, 30] . Although specula-
tive, MCPyV might infect single cells which then undergo 
neoplastic transformation and give rise to a  malignant tu-
mor. The tumor might become independent of the virus, 
which could persist in a ‘dormant’ state in isolated cells, 
similar to other members of the polyomavirus family such 
as BKV and JCV  [35] . Sequence analysis did not reveal 
mutations of the amplified MCPyV large T gene in EV-
associated skin neoplasms. This is in contrast to MCC, 
where truncating mutations of the MCPyV large T gene 
were identified  [36] . Still, the absence of mutations of the 
MCPyV large T gene in EV-associated skin lesions does 
not exclude a pathogenetic role for MCPyV. There may be 
alternative pathways by which MCPyV may contribute to 
the pathogenesis of NMSC in EV patients.
 Apart from pathogenetic aspects, the presence of 
MCPyV and EV HPV in all our EV patients could have 
diagnostic impact since EV is the only disease that is 
known so far to consistently harbor both viruses. The de-
tection of EV HPV and MCPyV simultaneously present in 
one or several lesions suspicious for EV may serve as an 
adjunctive diagnostic marker for this rare genodermatosis. 
This association is of particular importance since  EVER 
mutations have only recently been identified and the spec-
trum of  EVER mutations in EV has still to be  defined im-
plicating a need for additional diagnostic criteria.
 The presence of MCPyV in all EV patients and the on-
cogenic properties of MCPyV may suggest a pathogenetic 
model of how MCPyV could contribute to the can cerous 
progression of benign to malignant skin lesions, poten-
tially in synergy with HPV. However, the strong associa-
tion of EV HPV and MCPyV with EV does not prove a 
causative role per se, but rather suggests that these viruses 
contribute to the development of NMSC. To establish a 
causative role, several criteria have to be fulfilled  [37] . Fur-
ther studies are needed to confirm consistency of the as-
sociation, i.e. reproducibility of the findings by various in-
vestigators and, ideally, also different methods.
 In summary, EV may be redefined as a genodermato-
sis with a unique susceptibility to infection with both EV 
HPV and MCPyV, which may act as synergistic carcino-
genic cofactors in the development of NMSC in EV. In 
spite of the small cohort size, the present study suggests 
that EV could be the first genetic predisposition towards 
MCPyV infection and represent a model not only for 
HPV-associated, but also for MCPyV-associated cutane-
ous oncogenesis.
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